Ikena Oncology, Inc. (NASDAQ:IKNA – Get Rating) – Equities research analysts at William Blair issued their Q1 2024 earnings per share (EPS) estimates for shares of Ikena Oncology in a report issued on Tuesday, March 14th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($0.70) for the quarter. The consensus estimate for Ikena Oncology’s current full-year earnings is ($2.44) per share. William Blair also issued estimates for Ikena Oncology’s Q2 2024 earnings at ($0.75) EPS, Q3 2024 earnings at ($0.78) EPS, Q4 2024 earnings at ($0.82) EPS and FY2027 earnings at ($5.24) EPS.
A number of other research firms have also recently commented on IKNA. Credit Suisse Group lowered their target price on Ikena Oncology from $16.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday. HC Wainwright lowered their price objective on Ikena Oncology from $26.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, November 29th.
Ikena Oncology Stock Up 1.2 %
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in IKNA. Millennium Management LLC purchased a new position in Ikena Oncology during the fourth quarter valued at $27,000. Virtu Financial LLC purchased a new position in shares of Ikena Oncology in the second quarter worth $69,000. Dimensional Fund Advisors LP raised its stake in shares of Ikena Oncology by 14.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 28,682 shares of the company’s stock worth $77,000 after purchasing an additional 3,537 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Ikena Oncology by 163.4% in the second quarter. Cubist Systematic Strategies LLC now owns 20,720 shares of the company’s stock worth $92,000 after purchasing an additional 12,854 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Ikena Oncology by 25.4% in the first quarter. JPMorgan Chase & Co. now owns 17,172 shares of the company’s stock worth $104,000 after purchasing an additional 3,482 shares during the last quarter. Hedge funds and other institutional investors own 72.40% of the company’s stock.
Ikena Oncology Company Profile
Ikena Oncology, Inc, a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
- Get a free copy of the StockNews.com research report on Ikena Oncology (IKNA)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.